R&D News | pharmaphorum

News

Biomarkers ‘may predict dementia 15 years before diagnosis’

Researchers in the UK and China have used proteomics data from the UK Biobank to identify protein biomarkers in the blood that could give warning of dementia years before

News

Gilead to buy liver disease specialist CymaBay for $4.3bn

Gilead Sciences has beefed up its pipeline with an agreement to buy CymaBay Therapeutics and its seladelpar drug for rare liver disease primary biliary cholangitis (PBC),

News

FDA fast-tracks GSK’s chronic hep B therapy bepirovirsen

GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, will get a rapid six-month review from the FDA when it is filed for approval, said the drugmaker th

News

Apple devices enrich patent data in arthritis trial

It can be challenging to follow the course of rheumatoid arthritis accurately in clinical assessments and trials due to “subtle and unpredictable” changes in symptoms – bu

News

CSL’s post-heart attack therapy flunks big phase 3 test

Biotech giant CSL has seen almost 5% wiped off the value of its shares after one of its most anticipated pipeline products failed a phase 3 trial in heart attack patients.

News

Dermatology pharma Alys launches with $100m from Medicxi

European life sciences investor Medicxi has bundled together six privately-held companies with dermatology medicines in development under a single drugmaker – called Alys

Biomarkers ‘may predict dementia 15 years before diagnosis’

Gilead to buy liver disease specialist CymaBay for $4.3bn

FDA fast-tracks GSK’s chronic hep B therapy bepirovirsen

Apple devices enrich patent data in arthritis trial

CSL’s post-heart attack therapy flunks big phase 3 test

Dermatology pharma Alys launches with $100m from Medicxi

UK women's health firm Theramex sold for around £2.2bn

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks